SlideNewsroom Press Releases In the News Media Inquiries Videos Press Releases Exciting things are happening at Aulos™ Bioscience. Here is the latest news about our company and pipeline. May 15, 2024 Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007 ... April 24, 2024 Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting ... January 25, 2024 First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers ... December 18, 2023 Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors ... November 3, 2023 New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting ... October 14, 2023 New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ... October 4, 2023 Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ... September 27, 2023 Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting ... August 1, 2023 Aulos Bioscience Raises $20 Million in Series A Extension Financing From Apple Tree Partners ... May 25, 2023 Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells ... Prev1234Next
